synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-09. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
== Treatment == Surgery, if feasible, is the only curative therapy. If the tumor has metastasized (most commonly, to the liver) and is considered incurable, there are some promising treatment modalities, such as the radiopharmaceuticals Lutetium (177Lu) DOTA-octreotate) and 131I-mIBG (meta iodo benzyl guanidine) for arresting the growth of the tumors and prolonging survival in patients with liver metastases, though these are currently experimental. Chemotherapy is of little benefit and is generally not indicated. Octreotide or lanreotide (somatostatin analogues) may decrease the secretory activity of the carcinoid, and may also have an anti-proliferative effect. Interferon treatment is also effective, and usually combined with somatostatin analogues. As the metastatic potential of a coincidental carcinoid is probably low, the current recommendation is for follow up in 3 months with CT or MRI, labs for tumor markers such as serotonin, and a history and physical, with annual physicals thereafter.
The Mystery of the Yellow Room at Project Gutenberg The Mystery of the Yellow Room at Standard Ebooks The Mystery of the Yellow Room public domain audiobook at LibriVox L'univers de Joseph Rouletabille, rouletabille.perso.cegetel.net (in French) The Mystery of the Yellow Room, audio version, litteratureaudio.com (in French) The Mystery of the Yellow Room at IMDb
In 1945, Frederick Sanger described its use for determining the N-terminal amino acid in polypeptide chains, in particular insulin. Sanger's initial results suggested that insulin was a smaller molecule than previously estimated (molecular weight 12,000), and that it consisted of four chains (two ending in glycine and two ending in phenylalanine), with the chains cross-linked by disulfide bonds. Sanger continued work on insulin, using dinitrofluorobenzene in combination with other techniques, eventually resulted in the complete sequence of insulin (consisting of only two chains, with a molecular weight of 6,000). Following Sanger's initial report of the reagent, the dinitrofluorobenzene method was widely adopted for studying proteins, until it was superseded by other reagents for terminal analysis (e.g., dansyl chloride and later aminopeptidases and carboxypeptidases) and other general methods for sequence determination (e.g., Edman degradation). Dinitrofluorobenzene reacts with the amine group in amino acids to produce dinitrophenyl-amino acids. These DNP-amino acids are moderately stable under acid hydrolysis conditions that break peptide bonds. The DNP-amino acids can then be recovered, and the identity of those amino acids can be discovered through chromatography. More recently, Sanger's reagent has also been used for the rather difficult analysis of distinguishing between the reduced and oxidized forms of glutathione and cysteine in biological systems in conjunction with HPLC.
The 1970s saw a shift in audience tastes to high concept films, with five such films made by either George Lucas or Steven Spielberg topping the chart during the 1980s. The 21st century has seen an increasing dependence on franchises and adaptations, with the box-office dominance of films based on pre-existing intellectual property at record levels. Steven Spielberg (1975, 1981, 1982, 1989 and 1993) and Cecil B. DeMille (1932, 1947, 1949, 1952 and 1956) tie as the most represented directors on the chart with five films apiece occupying the annual top spot. William Wyler (1942, 1946, 1959 and 1968) and James Cameron (1991, 1997, 2009 and 2022) are each represented by four films, whilst D. W. Griffith (1915, 1916 and 1920), George Roy Hill (1966, 1969 and 1973) and the Russo brothers (2016, 2018 and 2019) all feature heavily with three films apiece. George Lucas directed three chart-toppers in 1977, 1999 and 2005, but also served in a strong creative capacity as a producer and writer in 1980, 1981, 1983, and 1989 as well. The following directors have also all directed two films on the chart: Frank Lloyd, King Vidor, Frank Capra, Michael Curtiz, Leo McCarey, Alfred Hitchcock, David Lean, Stanley Kubrick, Guy Hamilton, Mike Nichols, William Friedkin, Peter Jackson, Gore Verbinski, and Michael Bay; Mervyn LeRoy, Ken Annakin and Robert Wise are each represented by one solo credit and one shared credit, and John Ford co-directed two films.
=== Columbia University: 1933-1934 === In April 1933, Schoenheimer emigrated to the United States in response to the Nazi regime's policy for the dismissal of Jewish faculty in universities. He was offered work at Columbia University as an assistant professor, where he continued his research on metabolism and cholesterol synthesis, alongside Walter M. Sperry and David Rittenberg. In 1933, Germany entered a political crisis and saw the rise of Hitler and the Nazi Party, which led Schoenheimer into emigrating to the United States. Schoenheimer had Jewish heritage which he was conscious of despite his Family having converted to Christianity. Schoenheimer had joined a Jewish Youth Movement and was actively involved in the Zionist Organisation following WW1. Due to the situation in Germany at the time and the Nazi Policy dismissing Jewish faculty, Schoenheimer was unlikely to remain living in Germany. Ludwig Kast was informed of this situation and contacted U.S universities, Cornell and Columbia on behalf of Schoenheimer. Hans T. Clarke, the Chairman of the Biological Chemistry Department at the University of Columbia, invited Schoenheimer to work at the university. He began work in the Department of Biological Chemistry as a research assistant. The Josiah Macy Foundation provided his salary and research support whilst he worked at Columbia. At Columbia Schoenheimer was among others that shared similar interests in Biochemistry and wanted it to move in the direction of organic chemistry.
Sources: en.wikipedia.org
According to Simon Kellwaye (1593), one should "take a great Onyon, make a hole in the myddle of him, then fill the place with Mitridat or Triacle, and some leaues of Rue". Until as late as 1786, physicians in London were officially prescribing mithridate. According to historian Christopher Hill, Oliver Cromwell took a large dose of mithridate as a precaution against the plague and found it cured his acne. The term mithridate has come to refer to any generally all-purpose antidote.
Methionitazene (methylthionitazene) is a benzimidazole derivative which is an opioid designer drug. It was invented in the late 1950s as part of the original research into the "nitazene" group of opioids by CIBA in Switzerland, but as with all compounds from this group was never developed for legitimate medical uses. In early studies on mice, it was found to be around half the potency of the methoxy analogue metonitazene with around 50 times the analgesic potency of morphine, and significantly more potent than the ethylthio homologue, but more recent research using modern techniques found methionitazene and metonitazene to have a similar EC50 in vitro despite the methoxy compound having a stronger binding affinity at the mu opioid receptor.
Bariatric surgery is an effective method for obese and diabetic individuals with MASLD to induce weight loss and reduce or resolve MASH inflammation, including fibrosis, and improve longevity. For the AASLD, bariatric surgery can be considered only for MASH on a case-by-case basis by an experienced bariatric surgery program. Indeed, some individuals might develop new or worsened features of MASLD. About 92% of people with MASLD experienced an improvement in steatosis, and 70% a complete resolution after bariatric surgery. A preoperative diet such as a low-calorie diet or a very-low-calorie diet is usually recommended to reduce liver volume by 16–20%. Preoperative weight loss is the only factor associated with postoperative weight loss. Preoperative weight loss can reduce operative time and hospital stay, although there is insufficient evidence whether preoperative weight loss reduces long-term morbidity or complications. Weight loss and decreases in liver size may be independent of the amount of calorie restriction. The APWG on MASLD recommends bariatric surgery as a treatment option for those with class II obesity (BMI >32.5 kg/m2 for Asians, 35 kg/m2 for Caucasians). They consider its effects on improving liver-related complications as unproven yet, but it effectively increases longevity by improving cardiovascular factors. Surgery carries more risks for individuals with MASH cirrhosis, with a review estimating overall morbidity to be 21%.
In 1916, Grace acquired a controlling interest in the Pacific Mail Steamship Company. In 1921, Pacific received five 535 ft. President class ships from the United States Shipping Board for transpacific operation. In 1923, the US Shipping board decided to place the five ships up for bid and Dollar Shipping Company won the bid. With no large ships for the transpacific operations, Grace sold the Pacific Mail, its registered name, and goodwill to Dollar. Now without a transpacific service, Grace did not need the six intercoastal freighters and sold them to the American Hawaiian Line. At this time, Grace formed the Panama Mail Steamship Company, to operate the smaller ships that were formerly owned and used by the Pacific Mail in the Central American trade. These ships were not involved in the sale to Dollar. On the death of William R. Grace in 1904, he was succeeded by William L. Sauders as company president followed by Joseph Peter Grace Sr. (1872–1950) who became president in 1907. In 1938, the Colombian Line merged with Grace Line bringing an end to the Colombian Line. During World War II, Grace Lines operated transport for the U.S. War Shipping Administration, including the SS Sea Marlin. J. Peter Grace took over management of the company after his father suffered a stroke in 1945. After the war, the Grace line operated 23 ships totaling 188,000 gross tons, and 14 more on bareboat charters.
At first, some major cities or capitals formed local Juntas on the basis of laws from the Hispanic tradition. The armed conflicts started in 1809, with short-lived juntas established to govern in Chuquisaca, La Paz and Quito opposing the government of the Supreme Central Junta of Seville. Although various regions objected to many crown policies, "there was little interest in outright independence; indeed there was widespread support for the Spanish Central Junta formed to lead the resistance against the French". While some Spanish Americans believed that independence was necessary, most who initially supported the creation of the new governments saw them as a means to preserve the region's autonomy from the French. Although there had been research on the idea of a separate Spanish American ("creole") identity separate from that of Iberia, political independence was not initially the aim of most Spanish Americans, nor was it necessarily inevitable. French forces had taken over southern Spain and forced the Supreme Junta to seek refuge in the island-city of Cádiz. The escape to Cádiz and the dissolution of the Supreme Central Junta on 29 January 1810, because of the reverses suffered after the Battle of Ocaña by the Spanish forces paid with Spanish American money, set off another wave of juntas being established in the Americas. These juntas gained their own levels of independence and autonomy from Spain through declarations in 1808–1810.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.